Analyst Research

Report Title Price
Provider: New Constructs, LLC
$25.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

TG Therapeutics Inc's TG-1101 in combination with Ibrutinib demonstrates compelling clinical activity and safety profile in patients


Friday, 13 Jun 2014 05:30am EDT 

TG Therapeutics Inc:Announces preliminary clinical results from its ongoing Phase 2 study of TG-1101 (ublituximab).The company's novel glycoengineered anti-CD20 monoclonal antibody, in combination with ibrutinib (IMBRUVICA), the oral BTK inhibitor from Pharmacyclics/Janssen.TG-1101 in combination with ibrutinib was well tolerated in the 28 patients evaluable for safety, with Day one infusion related reactions (IRR) being the most frequently reported adverse event for TG-1101.All but one IRR were Grade one or two in severity and were manageable without dose reductions.Says Ibrutinib related adverse events included diarrhea and rash with one patient discontinuing treatment due to ibrutinib related diarrhea (only patient to discontinue from the study to date). 

Company Quote

16.45
0.75 +4.78%
19 Dec 2014